Skip to main content
Clinical Trials/NCT06548893
NCT06548893
Active, Not Recruiting
N/A

Group-based Acceptance and Commitment Therapy for Obsessive Compulsive Disorder: A Clinical Trial

Universidade Federal do Paraná1 site in 1 country24 target enrollmentAugust 10, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Obsessive-Compulsive Disorder
Sponsor
Universidade Federal do Paraná
Enrollment
24
Locations
1
Primary Endpoint
Yale-Brown Obsessive-Compulsive Scale (YBOCS)
Status
Active, Not Recruiting
Last Updated
last year

Overview

Brief Summary

The goal of this clinical trial is to learn if Acceptance and Commitment Therapy (ACT) + Exposure and Response Prevention (ERP) in Group is effective to Obsessive Compulsive Disorder (OCD) in adults.

Researchers will compare intervention to control group to see if those who attend the group therapy have better results than control group.

Participants will go through a 16-week group therapy based on a protocol designed by Michael Twohig (Twohig et al, 2018).

  • Participants will not have any medication adjustment during therapy
  • Participants will be assessed 3 times throughout the therapy, plus an assessment in a 6-month follow-up.

Detailed Description

The goal of this clinical trial is to learn if Acceptance and Commitment Therapy (ACT) + Exposure and Response Prevention (ERP) in Group is effective to Obsessive Compulsive Disorder (OCD) in adults. The main questions it aims to answer are: * Can ACT in groups help decrease the severity of OCD symptoms? * Can ACT in groups help increase psychological flexibility in this group? * Can ACT in groups help increase quality of life in this group? Researchers will compare intervention (n=16) to control group (n=8) to see if those who attend the group therapy have better results than control group. We will perform an unequal randomization in a 2:1 ratio, in blocks of 6, for allocation to each group. The assessor of the outcomes of interest will be blinded to the group to which the participant was assigned Participants will go through a 16-week group therapy based on a protocol designed by Michael Twohig (Twohig et al, 2018). * Participants will not have any medication adjustment during therapy * Participants will be assessed 3 times throughout the therapy, plus an assessment in a 6-month follow-up.

Registry
clinicaltrials.gov
Start Date
August 10, 2022
End Date
June 20, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Luciana Midori Samezima

Ms

Universidade Federal do Paraná

Eligibility Criteria

Inclusion Criteria

  • OCD diagnosis according to DMS-5/ Minimum score of 20 in YBOCS

Exclusion Criteria

  • Psychotic disorder, maniac episode, intellectual disability, Chemical dependency, Suicidal risk, another current psychotherapy

Outcomes

Primary Outcomes

Yale-Brown Obsessive-Compulsive Scale (YBOCS)

Time Frame: 10 months (4-month intervention + 6-month follow-up)

Measure for assessing the presence and severity of obsessive-compulsive disorder (OCD) symptoms.

Secondary Outcomes

  • Depression Anxiety and Stress Scale (DASS)(10 months (4-month intervention + 6-month follow-up))
  • Affective Style Questionnaire (ASQ)(10 months (4-month intervention + 6-month follow-up))
  • AAQ for Obsessions and Compulsions (AAQ-OC)(10 months (4-month intervention + 6-month follow-up))
  • Acceptance and Commitment Therapy Processes (CompACT)(10 months (4-month intervention + 6-month follow-up))
  • Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-SV)(10 months (4-month intervention + 6-month follow-up))
  • Clinical Global Impressions (CGI) Scale,(10 months (4-month intervention + 6-month follow-up))

Study Sites (1)

Loading locations...

Similar Trials